Medical Pharmacology: Diabetes Management Practice Questions
Return
Click on the correct answer.
Repaglinide (Pandin) is an oral insulin releasing agent belonging to the sulfonylurea class.
? True ? FalseRepaglinide (Pandin):
? Mechanism of action: stimulates insulin release in pancreatic
ß cells by closing K+ ATP potassium channels. ? Exhibits complete absorption following oral administration. ? Both ? NeitherRepaglinide (re PAG li nide) (Pandin):
? Following repaglinide-mediated ATP-dependent potassium channel blockade, the cell membrane is depolarized and calcium entry is facilitated. ? Exhibits an elimination half-life of about an hour ? Both ? NeitherRepaglinide is minimally metabolized and excreted as parent compound in the urine.
? True ? FalseRepaglinide (Prandin):
? Resembes glyburide ? Undergoes hepatic metabolism yielding a range of biologically active metabolites. ? Both ? NeitherRepaglinide administration is associated with a brief, rapid insulin pulse.
? True ? FalseRepaglinide can be used in combination with metformin.
? True ? FalseRepaglinide:
? Principal side effect is hypoglycemia. ? Repaglinide administration may exhibit secondary failure (a reduced drug efficacy) following initial enhanced glycemic control. ? Both ? NeitherRepaglinide metabolism is associated with:
? Liver ? Kidney ? Both ? NeitherRepaglinide should be administered cautiously with attention paid to dosing in patients exhibiting renal insufficiency.
? True ? FalsePotentiation of the action of repaglinide:
? May occur due to concurrent administration of drugs that displace repaglinide from plasma protein-binding locations. ? May occur due to concurrent administration of drugs which alter repaglinide metabolism by cytochrome P450 isoforms ? Both ? NeitherPrincipal labeled clinical indication for repaglinide administration: improvement of blood glucose levels in adults with type II diabetes mellitus.
? True ? FalseIn comparing repaglinide to glyburide,a long-duration sulfonylurea drug, repaglinide may be associated with less hypoglycemia.
? True ? FalseRepaglinide administration may be associated with weight gain.
? True ? False
Return
If you wish to return to the Table of Contents
in ENGLISH , press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Powers A D'Alessio D Chapters 47:
Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and
Hypoglycemia in Goodman & Gilman's: The Pharmcological
Basis of Therapeutics, 13e, (Brunto LL Hilal-Dandan R Knollmann
BC, eds) McGraw-Hill Education, 2018 .
Masharani U Diabetes
Mellitus (27-01) in Current Medical Diagnosis & Treatment (Papadakis
MA McPhee SJ Rabow MW McQuaid KR, eds) 61e McGraw Hill 2022.
Drugs (Access
Medicine)
